Rational engineering of minimally immunogenic nucleases for gene therapy
Abstract Genome editing using CRISPR-Cas systems is a promising avenue for the treatment of genetic diseases.However, cellular and humoral immunogenicity of genome editing tools, which originate from bacteria, complicates their clinical use.Here we report reduced immunogenicity (Red)(i)-variants of two clinically relevant nucleases, SaCas9 and AsCa